Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The global program to eliminate trachoma
- Strategy to eliminate blinding trachoma
- Guidelines for program implementation
- Mobilization for scaling up
- Basis of the global trachoma program
- Aim of the global program
- Limitations of the global program
- Control, elimination, and eradication
- Implementing and reaching elimination
- Getting the balance right
- Collateral benefits of the SAFE strategy
- A virtuous cycle via trachoma control
- Reduction in child mortality
- Challenges to eliminating trachoma
- Challenges to implementing at scale (1)
- Challenges to implementing at scale (2)
- Progress in the global trachoma program
- Trachoma-endemic district populations (1)
- Trachoma-endemic district populations (2)
- Reported trichiasis surgeries
- Total doses of Zithromax® shipped (by year)
- Total doses of Zithromax® shipped (cumulative)
- Countries supported by ITI
- ITI performance metrics
- Scale-down, 2014–2017
- Scale-up and scale-down summary
- Learn more at trachoma.org
Topics Covered
- The global program to eliminate trachoma
- Progress in the implementation of the global program to eliminate trachoma
- Challenges to reaching the elimination of trachoma
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Emerson, P. (2020, January 30). Overview of trachoma Part 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/ORDG7078.Export Citation (RIS)
Publication History
Financial Disclosures
- None
Overview of trachoma Part 2
Published on January 30, 2020
35 min
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dr. Paul Emerson.
I'm the Director of the International Trachoma Initiative here at
the Task Force for Global Health at Emory University, in Atlanta.
In the first part of the trachoma talk,
we discussed the epidemiology of trachoma and how we have mapped the disease.
In this part, we will discuss and we have applied our knowledge of the epidemiology and
global mapping to look at the elimination of trachoma as a public health problem,
and progress, and challenges to elimination.
0:39
The next section of the talk is about the program to eliminate trachoma,
and we're going to talk about the aims of the program,
some of the inbuilt compromises,
and how it's being delivered.
0:54
So the elimination of blinding trachoma is through
an integrated strategy with four pillars.
We've talked about the stages or the grades of the disease,
and the one in which a patient on immediate risk of blindness is TT.
TT is reversible through surgery and that forms the S of SAFE strategy.
We talked about how it is caused by a bacterial infection,
and bacterial means that it can be treated with antibiotics
and the antibiotics from the A part of the SAFE strategy,
the majority of that is azithromycin donated by Pfizer.
We've talked about how the disease is transmitted,
and it's transmitted mechanically from the eyes
and possibly from nasal secretions of people with disease,
particularly those with TI.
So that gives us F, facial cleanliness.
Washing your hands and face with soap and water can do two things; firstly,
it washes away those elementary bodies from
your face so that you are a reduced source of infection.
Secondly, it makes you less attractive to eye seeking flies,
so they are less likely to come to you and pick up the infection to pass it on.
Finally, the E is environmental improvement.
We've spoken about how it's an environmental disease.
Access to water is required for facial cleanliness and hygiene.
Hygiene promotion in the absence of water is
meaningless and needs to the access to water.
We also promote access to sanitation because the fly that transmits trachoma,
Musca sorbens, breeds in human feces,
but only human feces that lying on the soil surface.
If it's disposed of safely in latrines,
then it is no longer a source for fly breeding.
So that gives us the SAFE strategy.
It's a wonderful integrated strategy.